ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2017
[Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Single-patient single-cell RNA sequencing reveals neuroendocrine predominance and immunosuppression in small-cell lung cancer.Translational cancer research · 2026Article
- Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients.Frontiers in oncology · 2026Article
- Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.Translational lung cancer research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study is to explore cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) distribution and clinical value in liquid biopsy (such as blood) of small cell lung cancer (SCLC) patients.
methodsA total of 60 healthy and 290 chemotherapy-naive patients with SCLC were recruited. Venous blood samples were collected prior to chemotherapy (baseline) and after the second cycle of chemotherapy (2nd cycle), and flow cytometry was used to analyze the level of CTLA-4, PD-1 or PD-L1 with or without CD3, CD4, CD8 or CD25. Immunocytochemical method was used to detect PD-L1 expression in SCLC cell line H446.
resultsCells of CTLA-4+ and PD-1+ in SCLC peripheral blood were (1.56±1.24)% and (8.07±3.97)%; there is no significant difference between CD3+CTLA-4+ and CD4+CTLA-4+, (4.87±5.18)% and (3.85±2.60)%, but show lower expression than CD3+PD-1+ and CD4+PD-1+ (26.63±9.04)% and (20.79±9.41)%, respectively. However, the level of CD4+CD25+CTLA-4+ cells were remarkably higher in SCLC than that in control, (7.09±5.09)% vs (1.91±1.27)%, P<0.001 and CD8+PD-1+ cells were less in SCLC than that in control, (11.47±5.85)% vs (22.56±4.21)%, P<0.001, both of which were not associated with age, sex, smoke or disease stage. Level of CD4+CD25+CTLA-4+ cells and CD8+PD-1+ cells was dropped (5.11±2.60)% vs (6.94±4.91)% and (8.74±3.39)% vs (11.48±5.91)% after 2nd cycle compare to that at baseline (P<0.000,1). Neither the level of CD4+CD25+CTLA-4+ nor CD8+PD-1+ cells before or after treatment was related to progression-free disease or overall survival of patients. Although PD-L1 was highly expressed in H446 cell cytoplasm and membrane, it was rarely found in peripheral blood.
conclusionsThe data we presented here showed that CTLA-4 was highly expressed in regulatory T cells and PD-1 decreased in CD8+ T cells in peripheral blood of SCLC patients, suggesting their unique mechanisms involved in immune regulation. CD4+CD25+CTLA-4+ level changed after treatment implies its potential role in predicting treatment efficacy. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.